Molecular Techniques
25. Kline MJ, W ilkinson EJ, Askeland R,
et al. DNA tetraploidy in Feulgen-
stained bladder washings assessed by
image cytometry.
A n a l Q u a n t C yto l H is to l
26. Chrouser K, Leibovich B, Bergstralh E,
et al. Bladder cancer risk following
primary and adjuvant external beam
radiation for prostate cancer.
J U ro l
2005;174:107-110. discussion 110-111.
27. Bartoletti R, Cai T, Dal Canto M, et al.
M ultiplex polymerase chain reaction for
microsatellite analysis o f urine sediment
cells: a rapid and inexpensive method for
diagnosing and m onitoring superficial
transitional bladder cell carcinoma.
J U ro l
2006;175:2032-2037. discussion 2037.
28. Frigerio S, Padberg BC, Strebel RT, et al.
Improved detection o f bladder carci-
noma cells in voided urine by standard-
ized microsatellite analysis.
In t J C ancer
29. Dulaimi E, Uzzo RG, Greenberg RE, et al.
Detection o f bladder cancer in urine by a
tum or suppressor gene hypermethylation
C lin Cancer Res
30. Hoque MO, Begum S, Topaloglu O, et al.
Quantitation o f promoter m ethylation of
m ultiple genes in urine DNA and blad-
der cancer detection.
J N a tl C ancer In s t
31. Shin HJ, Shin DM, Tarco E, et al. Detec-
tion o f numerical aberrations o f chromo-
somes 7 and 9 in cytologic specimens of
pleural malignant mesothelioma.
C ancer
32. Illei PB, Rusch VW, Zakowski MF, et al.
Homozygous deletion of CDKN2A and
codeletion o f the methylthioadenosine
phosphorylase gene in the m ajority of
pleural mesotheliomas.
C lin C ancer Res
33. Wong L, Zhou J, Anderson D, et al.
Inactivation o f p16INK4a expression in
malignant mesothelioma by methylation.
L u n g C ancer
34. Sokolova IA, Bubendorf L, O'Hare A, et
al. A fluorescence in situ hybridization-
based assay for improved detection of
lung cancer cells in bronchial washing
C ancer
35. Romeo MS, Sokolova IA, M orrison LE,
et al. Chromosomal abnormalities in
non-small cell lung carcinomas and in
bronchial epithelia o f high-risk smok-
ers detected by multi-target interphase
fluorescence in situ hybridization.
J M o l
D ia g n
36. Bubendorf L, M uller P, Joos L, et al.
Multitarget FISH analysis in the diag-
nosis o f lung cancer.
A m J C lin P a th o l
37. Halling KC, Rickman OB, Kipp BR, et al.
A comparison of cytology and fluores-
cence in situ hybridization for the detec-
tion o f lung cancer in bronchoscopic
C hest
38. Jiang F, Caraway NP, Nebiyou Bekele B,
et al. Surfactant protein A gene deletion
and prognostics for patients w ith stage I
non-small cell lung cancer.
C lin C ancer
39. Li R Todd NW, Qiu Q, et al. Genetic dele-
tions in sputum as diagnostic markers for
early detection of stage I non-small cell lung
C lin Cancer Res
40. Schmiemann V, Bocking A, Kazimirek
M, et al. Methylation assay for the
diagnosis o f lung cancer on bronchial
aspirates: a cohort study.
C lin C ancer Res
41. Belinsky SA, Liechty KC, Gentry FD, et al.
Promoter hypermethylation o f multiple
genes in sputum precedes lung cancer
incidence in a high-risk cohort.
C ancer
42. Shivapurkar N, Stastny V, Suzuki M, et al.
Application o f a methylation gene panel
by quantitative PCR for lung cancers.
C ancer L e tt
43. Jaeckle KA, Ballman KV, Rao RD, et al.
Current strategies in treatment o f oligo-
dendroglioma: evolution o f molecular
signatures of response.
J C lin O ncol
44. Scheie D, Andresen PA, Cvancarova M,
et al. Fluorescence in situ hybridization
(FISH) on touch preparations: a reliable
method for detecting loss of heterozygosity
at 1p and 19q in oligodendroglial tumors.
A m J Surg P a th o l
45. Brankley SM, Wang KK, Harwood AR,
et al. The development o f a fluorescence
in situ hybridization assay for the detec-
tion o f dysplasia and adenocarcinoma
in Barrett's esophagus.
J M o l D ia g n
46. DeHaan RD, Kipp BR, Smyrk TC, et al.
An assessment o f chromosomal altera-
tions detected by fluorescence in situ
hybridization and p16 expression in
sporadic and primary sclerosing cholangi-
tis-associated cholangiocarcinomas.
H u m
P a th o l
47. Klump B, Hsieh CJ, Dette S, et al.
Promoter methylation o f INK4a/ARF as
detected in bile-significance for the dif-
ferential diagnosis in biliary disease.
C lin
C ancer Res
48. Yang B, House MG, Guo M, et al. Pro-
moter methylation profiles o f tum or
suppressor genes in intrahepatic and
extrahepatic cholangiocarcinoma.
M o d
P a th o l
49. Khalid A, Pal R, Sasatomi E, et al. Use o f
microsatellite marker loss o f heterozygos-
ity in accurate diagnosis of pancreatico-
biliary malignancy from brush cytology
G u t
50. Willmore-Payne C, Volmar KE, Huening
MA, et al. Molecular diagnostic testing as
an adjunct to morphologic evaluation of
pancreatic ductal system brushings: poten-
tial augmentation for diagnostic sensitiv-
D ia g n C ytopathol
51. Tomlins SA, Rhodes DR, Perner S, et al.
Recurrent fusion o f TMPRSS2 and ETS
transcription factor genes in prostate
52. W olff AC, Hammond ME, Schwartz JN, et
al. American Society o f Clinical Oncology/
College o f American Pathologists guideline
recommendations for human epidermal
growth factor receptor 2 testing in breast
J C lin O ncol
53. Press MF, Sauter G, Bernstein L, et al.
Diagnostic evaluation o f HER-2 as
a molecular target: an assessment of
accuracy and reproducibility o f labora-
tory testing in large, prospective, rand-
omized clinical trials.
C lin C ancer Res
54. Tapia C, Savic S, Wagner U, et al. HER2
gene status in primary breast cancers and
matched distant metastases.
B reast C ancer
55. Vocaturo A, Novelli F, Benevolo M,
et al. Chromogenic in situ hybridization
to detect HER-2/neu gene amplification
in histological and ThinPrep-processed
breast cancer fine-needle aspirates: a sen-
sitive and practical method in the trastu-
zumab era.
O ncolog ist
56. Tanner M, Isola J, W iklund T, et al. Topo-
isomerase IIalpha gene amplification
predicts favorable treatment response
to tailored and dose-escalated anthra-
cycline-based adjuvant chemotherapy
in HER-2/neu-amplified breast cancer:
Scandinavian Breast Group Trial 9401.
J C lin O ncol
57. Holst F, Stahl PR, Ruiz C, et al. Estrogen
receptor alpha (ESR1) gene amplification
is frequent in breast cancer.
N a t G enet
58. Sequist LV, Bell DW, Lynch TJ, et al.
Molecular predictors o f response to epi-
dermal growth factor receptor antagonists
in non-small-cell lung cancer.
J C lin O ncol
59. Riely GJ, Politi KA, M iller VA, et al.
Update on epidermal growth factor recep-
tor mutations in non-small cell lung can-
C lin C ancer Res
60. Engelman JA, Zejnullahu K, M itsudom i T,
et al. MET amplification leads to gefitinib
resistance in lung cancer by activating
ERBB3 signaling.
61. Cappuzzo F, Hirsch FR, Rossi E, et al.
Epidermal growth factor receptor gene
and protein and gefitinib sensitivity in
non-small-cell lung cancer.
J N a tl C ancer
In s t
62. de Villiers EM, Fauquet C, Broker TR,
et al. Classification o f papillomaviruses.
V iro lo g y
63. Jacobs MV, Snijders PJ, van den Brule AJ,
et al. A general primer GP5+/GP6(+)-
mediated PCR-enzyme immunoassay
method for rapid detection o f 14 high-
risk and 6 low-risk human papilloma-
virus genotypes in cervical scrapings.
J C lin M ic ro b io l
64. Gravitt PE, Peyton CL, Alessi TQ,
et al. Improved amplification o f genital
human papillomaviruses.
J C lin M ic ro b io l
65. Kleter B, van Doorn LJ, ter Schegget J,
et al. Novel short-fragment PCR assay for
highly sensitive broad-spectrum detection
o f anogenital human papillomaviruses.
A m J P a th o l
66. Puranen M, Saarikoski S, Syrjanen K,
et al. Polymerase chain reaction ampli-
fication of human papillomavirus DNA
from archival, Papanicolaou-stained cer-
vical smears.
A cta C yto l
67. Monsonego J, Bohbot JM, Pollini G, et
al. Performance o f the Roche AMPLICOR
human papillomavirus (HPV) test in pre-
diction o f cervical intraepithelial neopla-
sia (CIN) in women w ith abnormal PAP
G ynecol O ncol
68. Stevens
Garland SM, Tabrizi SN.
Human papillomavirus genotyping using
a modified linear array detection proto-
J V iro l M ethod s
previous page 1072 ComprehensiveCytopathology 1104p 2008 read online next page 1074 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off